摘要
目的:探讨甲状腺癌细胞中胰高糖素样肽-1(Glucagon like peptide-1,GLP-1)受体的表达情况,及其对癌细胞生长和增殖的影响。方法:Western blot法检测甲状腺乳头状癌(Papillary thyroid cancer,PTC)细胞系GLP-1受体表达情况。采用四甲基偶氮唑蓝法(MTT)评价两种GLP-1受体激动剂艾塞那肽和利拉鲁肽处理后细胞增殖情况。Western blot法测定细胞中蛋白激酶B(Protein kinase B,Akt)及细胞外信号调节蛋白激酶1/2(Extracellular signal-regulated kinase 1/2,Erk1/2)等细胞信号通路相关蛋白的表达。结果:PTC细胞系BCPAP、TPC-1中均可检测到GLP-1受体的表达。艾塞那肽和利拉鲁肽分别以1nmol/L、10noml/L和100nmol/L作用于细胞24h、48h和72h后,实验组细胞增殖率与对照组相比无统计学差异。不同浓度艾塞那肽和利拉鲁肽作用细胞24h后,实验组Akt和Erk蛋白表达水平及其磷酸化程度与对照组相比无统计学差异。结论:人甲状腺乳头状癌细胞中有GLP-1受体的表达。但是,GLP-1受体激动剂对甲状腺癌细胞的增殖无明显促进作用。同时,GLP-1受体激动剂对与细胞增殖密切相关的Akt和Erk通路无明显作用。
Objective ： To investigate the expression of Glucagon like peptide - 1 receptor in papillary thyroid canc- er and its effect on growth and proliferation in PTC. Methods： GLP - 1 receptor expression in cells was analyzed by Western blot. Cell growth and proliferation were evaluated by MTT assays. The expression of Akt/p - Akt and Erk/ p - Erk were measured by Western blot. Results： The GLP - 1 receptor was expressed in PTC cell lines. MTY assay showed that exenatide and liraglutide had no effect on growth and proliferation of BCPAP and TPC - 1. When treated with exenatide and liraglutide for 24h, there was no change in expression of Akt/p - Akt and Erk/p - Erk in PTC cell lines. Condusion：PTC cell lines express the GLP - 1 receptor. However, the activate of GLP - 1 receptor makes no difference on growth and proliferation in PTC cell lines, and have no effect on Akt and Erk pathway.
出处
《现代肿瘤医学》
CAS
2015年第8期1033-1036,共4页
Journal of Modern Oncology
基金
中华医学会临床医学科研专项资金-施贵宝内分泌糖尿病研究项目(编号:13040480433)
辽宁省高等学校创新团队项目(编号:LT2012015)
沈阳市科学技术项目(编号:F11-244-1-00)
